|
Alexza Pharmaceuticals, Inc. (Alexza) is a pharmaceutical company focused on the research, development, and commercialization of products for the acute treatment of central nervous system (CNS) conditions. The Company’s product candidates are based on its technology, the Staccato system. The Staccato system vaporizes an excipient-free drug to form a condensation aerosol that, when inhaled, allows for systemic drug delivery. Alexza has five other product candidates in various stages of clinical development. On August 26, 2009, Alexza completed the acquisition of Symphony Allegro, Inc.
|
|
Around The Net
You are reading news provided by a variety of web sources.
Drug Pipeline
| Drug Name | Type Of Drug | FDA Status | Drug Phase |
| AZ-004 |
Other
| Pending Decision | NDA |
| AZ-001 |
Pain Management
| Unknown | Phase 2 |
| AZ-104 |
Pain Management
| Unknown | Phase 2 |
| AZ-003 |
Pain Management
| Unknown | Phase 1 |
| AZ-002 |
Other
| Unknown | Phase 2 |
| AZ-007 |
Other
| Unknown | Phase 1 |
Events
Earnings:
Q1 - 2010 Earnings Release at 4PM.
Earnings:
Q1 - 2010 Earnings Release at 4PM.
Presentation:
Presentation at JMP Securities Research Conference.
Meeting:
2010 Annual Meeting of Stockholders - 2:30PM PT
FDA Decision:
FDA decision date.
(relates to the drug AZ-004)
Add New Event
In order to write a comment you must first login.
Login or Register (for free!)
Add Event
Important Links
PharmaInvestor / 5/18/2010 3:16:20 PM
Add New Link
In order to write a comment you must first login.
Login or Register (for free!)
Add Link
|
ALXA
$3.02
9/3/2010 4:00:00 PM
Sponsors
|